Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 923-930

  Imaoka, Natsuko ^a,b   Hiratsuka, Masaharu ^b   Osaki, Mitsuhiko ^a,b   Kamitani, Hideki ^b   Kambe, Atsushi ^b   Fukuoka, Junya ^c   Kurimoto, Masanori ^d   Nagai, Shoichi ^a,d   Okada, Futoshi ^b   Watanabe, Takashi ^b   Ohama, Eisaku ^b   Kato, Shinsuke ^b   Oshimura, Mitsuo ^a,b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOYAMA UNIVERSITY HOSPITAL   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Glioblastoma; Immunohistochemistry; Malignancy; Sirtuin 2 protein; Survival

Indexed keywords

POLYCLONAL ANTIBODY; SIRTUIN 2;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL PREDICTION; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; ANIMALS; BRAIN NEOPLASMS; CELL NUCLEUS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PROGNOSIS; SIRTUIN 2; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84865345111     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1872     Document Type: Article

References (31)

1. Huse JT and Holland EC: Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331, 2010.
2. Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387, 2000.
3. Shete S, Hosking FJ, Robertson LB, et al: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41: 899-904, 2009.
4. Wrensch M, Jenkins RB, Chang JS, et al: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 41: 905-908, 2009.
5. Di Rocco F, Carroll RS, Zhang J and Black PM: Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42: 341-346, 1998.
6. Xiao A, Wu H, Pandolfi PP, Louis DN and Van Dyke T: Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1: 157-168, 2002.
7. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453, 2007.
8. Hiratsuka M, Inoue T, Toda T, et al: Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 309: 558-566, 2003.
9. Michan S and Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-13, 2007.
10. North BJ and Verdin E: Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One 2: e784, 2007.
11. Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435, 2004.
12. Pandithage R, Lilischkis R, Harting K, et al: The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol 180: 915-929, 2008.
13. Harting K and Knoll B: SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. Eur J Cell Biol 89: 262-269, 2010.
14. Inoue T, Nakayama Y, Yamada H, et al: SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle 8: 1279-1291, 2009.
15. Inoue T, Hiratsuka M, Osaki M and Oshimura M: The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 6: 1011-1018, 2007.
16. Inoue T, Hiratsuka M, Osaki M, et al: SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 26: 945-957, 2007.
17. Kato M, Brijlall D, Adler SA, Kato S and Herz F: Effect of hyperosmolarity on alkaline phosphatase and stress-response protein 27 of MCF-7 breast cancer cells. Breast Cancer Res Treat 23: 241-249, 1992.
18. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
19. Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10: 4314-4324, 2004.
20. Werner HB, Kuhlmann K, Shen S, et al: Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci 27: 7717-7730, 2007.
21. Holland EC: Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2: 120-129, 2001.
22. Zhu Y, Guignard F, Zhao D, et al: Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8: 119-130, 2005.
23. Nahhas F, Dryden SC, Abrams J and Tainsky MA: Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem 303: 221-230, 2007.
24. Lee YS, Lim KH, Guo X, et al: The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68: 7561-7569, 2008.
25. Schiffer D, Cavalla P, Chio A, Richiardi P and Giordana MT: Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 34: 31-35, 1997.
26. Di X, Nishizaki T, Harada K, Kajiwara K, Nakayama H and Ito H: Proliferative potentials of glioma cells and vascular components determined with monoclonal antibody MIB-1. J Exp Clin Cancer Res 16: 389-394, 1997.
27. Uematsu M, Ohsawa I, Aokage T, et al: Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 72: 231-238, 2005.
28. Johannessen AL and Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12: 143-147, 2006.
29. Moskowitz SI, Jin T and Prayson RA: Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 76: 193-200, 2006.
30. Rushing EJ, Sandberg GD and Horkayne-Szakaly I: High-grade astrocytomas show increased Nestin and Wilms' tumor gene (WT1) protein expression. Int J Surg Pathol 18: 255-259, 2010.
31. Ducray F, Idbaih A, Wang XW, Cheneau C, Labussiere M and Sanson M: Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ther 11: 781-789, 2011.